EFTA01989563.pdf

DataSet-10 2 pages 248 words document
👁 1 💬 0
📄 Extracted Text (248 words)
To: 'eeva ation mail.com[[email protected]: Jeeevacationggmall.comj From: Sent: Sun 10/21/2012 3:31:31 PM Subject: Re: Ok Sent from my iPhone On Oct 21, 2012, at 11:16 AM, J [email protected]> wrote: We left my exercise belt , by a new one Sent from my iPad On Oct 21, 2012, at 10:59 AM, la wrote: Thank ou I have also researched It is a capsule with powder in that burns but I will try. Sent from my iPhone On Oct 21, 2012, at 7:14 AM, Jeffrey Epstein <[email protected]> wrote: Generalized Anxiety Disorder — It is generally agreed that episodes of generalized anxiety disorder require several months or longer of sustained pharmacological therapy. Maintenance of efficacy in GAD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered in a dose range of 60-120 mg once daily. Patients should be periodically reassessed to determine the continued need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (JA,2)]. *********************************************************** The information contained in this communication is EFTA_R1_00481839 EFTA01989563 confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_00481840 EFTA01989564
ℹ️ Document Details
SHA-256
8366e289cb30f04fe340a91f24030c51c5345665d18d8bbf9e52a77beb15b3da
Bates Number
EFTA01989563
Dataset
DataSet-10
Type
document
Pages
2

Community Rating

Sign in to rate this document

📋 What Is This?

Loading…
Sign in to add a description

💬 Comments 0

Sign in to join the discussion
Loading comments…
Link copied!